FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108390306> ?p ?o ?g. }

• W2108390306 abstract "Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up.Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score.Increased Mammostrat scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients.This is the fifth independent study providing evidence that Mammostrat can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer." @default.
• W2108390306 created "2016-06-24" @default.
• W2108390306 creator A5006199301 @default.
• W2108390306 creator A5006840242 @default.
• W2108390306 creator A5007286394 @default.
• W2108390306 creator A5028987280 @default.
• W2108390306 creator A5033135467 @default.
• W2108390306 creator A5034318098 @default.
• W2108390306 creator A5041581672 @default.
• W2108390306 creator A5044861463 @default.
• W2108390306 creator A5049740473 @default.
• W2108390306 creator A5055312766 @default.
• W2108390306 creator A5062357385 @default.
• W2108390306 creator A5074787333 @default.
• W2108390306 creator A5079776850 @default.
• W2108390306 creator A5089730402 @default.
• W2108390306 creator A5091359426 @default.
• W2108390306 date "2010-07-08" @default.
• W2108390306 modified "2023-10-10" @default.
• W2108390306 title "Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy" @default.
• W2108390306 cites W1961026612 @default.
• W2108390306 cites W1976900020 @default.
• W2108390306 cites W2050401007 @default.
• W2108390306 cites W2050818040 @default.
• W2108390306 cites W2097255042 @default.
• W2108390306 cites W2100210398 @default.
• W2108390306 cites W2105882193 @default.
• W2108390306 cites W2106642283 @default.
• W2108390306 cites W2118413367 @default.
• W2108390306 cites W2121800090 @default.
• W2108390306 cites W2124640147 @default.
• W2108390306 cites W2127511865 @default.
• W2108390306 cites W2128985829 @default.
• W2108390306 cites W2130588419 @default.
• W2108390306 cites W2148867790 @default.
• W2108390306 cites W2155357724 @default.
• W2108390306 cites W2163688875 @default.
• W2108390306 cites W2171278509 @default.
• W2108390306 doi "https://doi.org/10.1186/bcr2604" @default.
• W2108390306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2949634" @default.
• W2108390306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20615243" @default.
• W2108390306 hasPublicationYear "2010" @default.
• W2108390306 type Work @default.
• W2108390306 sameAs 2108390306 @default.
• W2108390306 citedByCount "108" @default.
• W2108390306 countsByYear W21083903062012 @default.
• W2108390306 countsByYear W21083903062013 @default.
• W2108390306 countsByYear W21083903062014 @default.
• W2108390306 countsByYear W21083903062015 @default.
• W2108390306 countsByYear W21083903062016 @default.
• W2108390306 countsByYear W21083903062017 @default.
• W2108390306 countsByYear W21083903062018 @default.
• W2108390306 countsByYear W21083903062019 @default.
• W2108390306 countsByYear W21083903062020 @default.
• W2108390306 countsByYear W21083903062021 @default.
• W2108390306 countsByYear W21083903062022 @default.
• W2108390306 countsByYear W21083903062023 @default.
• W2108390306 crossrefType "journal-article" @default.
• W2108390306 hasAuthorship W2108390306A5006199301 @default.
• W2108390306 hasAuthorship W2108390306A5006840242 @default.
• W2108390306 hasAuthorship W2108390306A5007286394 @default.
• W2108390306 hasAuthorship W2108390306A5028987280 @default.
• W2108390306 hasAuthorship W2108390306A5033135467 @default.
• W2108390306 hasAuthorship W2108390306A5034318098 @default.
• W2108390306 hasAuthorship W2108390306A5041581672 @default.
• W2108390306 hasAuthorship W2108390306A5044861463 @default.
• W2108390306 hasAuthorship W2108390306A5049740473 @default.
• W2108390306 hasAuthorship W2108390306A5055312766 @default.
• W2108390306 hasAuthorship W2108390306A5062357385 @default.
• W2108390306 hasAuthorship W2108390306A5074787333 @default.
• W2108390306 hasAuthorship W2108390306A5079776850 @default.
• W2108390306 hasAuthorship W2108390306A5089730402 @default.
• W2108390306 hasAuthorship W2108390306A5091359426 @default.
• W2108390306 hasBestOaLocation W21083903061 @default.
• W2108390306 hasConcept C121608353 @default.
• W2108390306 hasConcept C126322002 @default.
• W2108390306 hasConcept C143998085 @default.
• W2108390306 hasConcept C193270364 @default.
• W2108390306 hasConcept C2776694085 @default.
• W2108390306 hasConcept C2777176818 @default.
• W2108390306 hasConcept C2777982462 @default.
• W2108390306 hasConcept C2778311097 @default.
• W2108390306 hasConcept C2780140570 @default.
• W2108390306 hasConcept C2780275930 @default.
• W2108390306 hasConcept C2908647359 @default.
• W2108390306 hasConcept C38180746 @default.
• W2108390306 hasConcept C509974204 @default.
• W2108390306 hasConcept C530470458 @default.
• W2108390306 hasConcept C71924100 @default.
• W2108390306 hasConcept C99454951 @default.
• W2108390306 hasConceptScore W2108390306C121608353 @default.
• W2108390306 hasConceptScore W2108390306C126322002 @default.
• W2108390306 hasConceptScore W2108390306C143998085 @default.
• W2108390306 hasConceptScore W2108390306C193270364 @default.
• W2108390306 hasConceptScore W2108390306C2776694085 @default.
• W2108390306 hasConceptScore W2108390306C2777176818 @default.
• W2108390306 hasConceptScore W2108390306C2777982462 @default.
• W2108390306 hasConceptScore W2108390306C2778311097 @default.
• W2108390306 hasConceptScore W2108390306C2780140570 @default.
• W2108390306 hasConceptScore W2108390306C2780275930 @default.

• next